Order your subscription today to gain instant online access!
The C-MAP™ Canadian Drug Benefit Plans Reference Guide is the authoritative source for comprehensive and up-to-date information on Canadian reimbursement and market access for pharmaceutical market access specialists.
The publication highlights each of the relevant agencies, organizations and drug plans operating in the ... Read More
20
Jan2016
21
Dec2015
The Patented Medicines Prices Review Board (PMPRB) has released their highly anticipated Strategic Plan 2015-2018. The PMPRB’s three-year strategic plan includes four new strategic objectives, a reinvigorated mission statement, and a vision as to how the organization can work with partners and stakeholders in advancing the common goal of ... Read More
14
Dec2015
The Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, has released the Annual Report for the year ended December 31, 2014. This year, the format has been updated, adopting a more user-friendly design highlighting the PMPRB activities and emphasizing important trends.
Below ... Read More
14
Dec2015
CADTH is currently updating the third edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada. To help with this initiative, CADTH is inviting interested stakeholders to provide input. These guidelines detail best practices for conducting economic evaluations and are used to standardize and facilitate economic evaluations while ... Read More
25
Nov2015
PDCI has developed considerable expertise assisting manufacturers with product listing agreements(PLAs) through the pan-Canadian Pharmaceutical Alliance (pCPA), with individual provinces (including Quebec) and with private payers. With the formalization of the pCPA process and private payers moving aggressively into the PLA environment (see PDCIs white paper), PDCI is growing ... Read More
13
Nov2015
2015 FCA 249 Attorney General of Canada v Sandoz (A-302-14) & v ratiopharm (now Teva) (A-303-14).
The central issue in both appeals is whether the Federal Court judge properly held that Sandoz and ratiopharm (collectively the respondents) fell outside of the jurisdiction of the Board as they were not “patentees” within ... Read More
03
Nov2015
On Friday, October 30, 2015 PDCI presented a webinar entitled “Market Access Climate Change: the Evolving Impact of Product Listing Agreements”.
The purpose of this webinar was to:
Shed light on the recent developments at the pCPA; and
Enhance the understanding of the growing practice of PLA negotiations in the private payer ... Read More
26
Oct2015
As requested by stakeholders, the deadline for the following CADTH calls for stakeholder input has been extended to November 9, 2015 at 5:00 p.m. EST:
CDR Update – Issue 111
CADTH Consultation: Revisions to the Common Drug Review Procedure
Invites stakeholder comments and feedback on the following proposed revisions to the Procedure ... Read More
26
Oct2015
The Canadian Association for Healthcare Reimbursement (CAHR) is hosting a one-day event to discuss two key issues of relevance to the pharmaceutical and life sciences sectors following the October 2015 federal election. Maclean’s magazine’s and event moderator, Paul Wells, will be present to share his knowledge on innovation policy and ... Read More
06
Oct2015
Based on stakeholder feedback received in May 2015, CADTH has announced that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately.
Please note that for ... Read More